Lumen Bio utilizes patented technology to develop biologic drugs and vaccine candidates at a lower cost and reduced risk compared to traditional methods. The company targets diseases that have been neglected by conventional drug-making tools, aiming to improve access to effective treatments for conditions like C. difficile and metabolic diseases.
Funding
$30M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
GFRFTSWGWW+1Founders
Product
Problem
Traditional methods of biologic drug and vaccine development are often expensive, time-consuming, and carry significant risk, leading to neglect of treatments for diseases that disproportionately affect underserved populations or have proven difficult to address with conventional drug-making tools.
Solution
Lumen Bioscience is developing biologic drugs and vaccines using a patented, scalable technology based on spirulina, aiming to lower costs and reduce development risks compared to traditional methods. This platform enables the production of oral biologics at scales previously unattainable, opening avenues for treating and preventing diseases that have been neglected due to the limitations of conventional drug development. By leveraging spirulina as a biologics factory, Lumen seeks to transform the accessibility and affordability of biologic drugs, particularly for conditions like C. difficile, metabolic diseases, and traveler's diarrhea. The company's approach focuses on indications where traditional drug-making tools have fallen short, with the goal of improving global access to effective treatments.
Target Audience
The primary target audience includes individuals and communities affected by neglected diseases, as well as strategic partners and collaborators in the fields of global health and pharmaceutical development.
Features
- Patented technology for rapid and low-cost development of biologic drugs and vaccines
- Scalable production of oral biologics using spirulina
- Focus on diseases neglected by traditional drug development
- Pipeline includes treatments for C. difficile, metabolic diseases, COVID-19-related GI issues, and traveler's diarrhea
- Strategic collaborations with organizations like the Gates Foundation and NIH